I have a lot going on so I just glanced at the posts and I'll try to answer everything quickly. Nemus has the rights to 6 patents. 5 are posted on their website. They also have the rights to all research being done that could develop into patents and first right of refusal for any other patents not currently in the picture. Nemus has wide lattitude in the licensing agreements as long as they meet milestones and the financial terms of the agreements.
Ladin and his group put in $2 million at .50 per share with no protection. All other investors received price protection for the calendar year they invested.
Everyone who has invested in the PIPES are wealthy. They are long time friends and associates of the Board. They invested with the commitment that they would ride this out for the long term. Meaning, they wouldn't sell until an uplist and with a price target of $10. It's not in writing but more of a gentlemen's agreement. I would estimate that besides the 3 plus million shares that are out there, another 5 million could hit the market from the 10% who are not tied to the Board. I could see them sell in the $3 plus range. All the rest are very wealthy and are in it because they believe this is a groundbreaking company with enormous potential. They believe the true valuation is $10 pps right now. Sounds crazy but since it's a penny stock in this sector, it gets no coverage by analysts and no valuations by credible publications. The NYSE wants Nemus to be their first cannabinoid listing and once it happens, Nemus will receive a lot of coverage.
In my opinion, they are working on a develpment deal and that along with other news will drive the price. Uplisting is a priority but not with a reverse split and should be able to pull that off with news. This has all been plotted out and the group that put in $20 million was very satisfied with the uplisting strategy.
